High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins

Autor: Elisabeth Brouwer, Marc Bijl, Frederico Augusto Gurgel Pinheiro, Luis Eduardo Coelho Andrade, Cees G. M. Kallenberg, Kornelis S M van der Geest, Johanna Westra, Alexandre Wagner Silva de Souza, Emilia Inoue Sato, Ana Cecília Diniz Oliveira
Přispěvatelé: Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Translational Immunology Groningen (TRIGR), Groningen Institute for Organ Transplantation (GIOT)
Rok vydání: 2014
Předmět:
Male
medicine.medical_specialty
Pathology
INTERLEUKIN-6
Immunology
Takayasu arteritis
Giant Cell Arteritis
POLYMYALGIA-RHEUMATICA
chemical and pharmacologic phenomena
Enzyme-Linked Immunosorbent Assay
Gastroenterology
THERAPY
Sensitivity and Specificity
CLASSIFICATION
Disease activity
Polymyalgia rheumatica
Rheumatology
GIANT-CELL ARTERITIS
RHEUMATOLOGY 1990 CRITERIA
Large vessel vasculitis
Internal medicine
medicine
Immunology and Allergy
Humans
HMGB1 Protein
Interleukin 6
Aged
biology
business.industry
Age Factors
Middle Aged
medicine.disease
SERUM HMGB1 LEVELS
Takayasu Arteritis
Giant cell arteritis
Cross-Sectional Studies
ROC Curve
Area Under Curve
biology.protein
Biomarker (medicine)
Female
TAKAYASUS-ARTERITIS
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Biomarkers
Research Article
Zdroj: Arthritis Research & Therapy
Arthritis Research and Therapy, 17(1):158. BioMed Central Ltd.
ISSN: 1478-6362
Popis: Introduction: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large vessel vasculitides (LVV) that usually present as granulomatous inflammation in arterial walls. High mobility group box 1 (HMGB1) is a nuclear protein that acts as an alarmin when released by dying or activated cells. This study aims to evaluate whether serum HMGB1 can be used as a biomarker in LVV.Methods: Twenty-nine consecutive TA patients with 29 healthy controls (HC) were evaluated in a cross-sectional study. Eighteen consecutive GCA patients with 16 HC were evaluated at the onset of disease and some of them during follow-up. Serum HMGB1 levels were measured by enzyme-linked immunosorbent assay.Results: In GCA patients at disease onset mean serum HMGB1 levels did not differ from HC (5.74 +/- 4.19 ng/ml vs. 4.17 +/- 3.14 ng/ml; p = 0.230). No differences in HMGB1 levels were found between GCA patients with and without polymyalgia rheumatica (p = 0.167), ischemic manifestations (p = 0.873), systemic manifestations (p = 0.474) or relapsing disease (p = 0.608). During follow-up, no significant fluctuations on serum HMGB1 levels were observed from baseline to 3 months (n = 13) (p = 0.075), 12 months (n = 6) (p = 0.093) and at the first relapse (n = 4) (p = 0.202). Serum HMGB1 levels did not differ between TA patients and HC [1.19 (0.45-2.10) ng/ml vs. 1.46 (0.89-3.34) ng/ml; p = 0.181] and no difference was found between TA patients with active disease and in remission [1.31 (0.63-2.16) ng/ml vs. 0.75 (0.39-2.05) ng/ml; p = 0.281]. HMGB1 levels were significantly lower in 16 TA patients on statins compared with 13 patients without statins [0.59 (0.29-1.46) ng/ml vs. 1.93 (0.88-3.34) ng/ml; p = 0.019]. Age was independently associated with higher HMGB1 levels regardless of LVV or control status.Conclusions: Patients with TA and GCA present similar serum HMGB1 levels compared with HC. Serum HMGB1 is not useful to discriminate between active disease and remission. In TA, use of statins was associated with lower HMGB1 levels. HMGB1 is not a biomarker for LVV.
Databáze: OpenAIRE
Externí odkaz: